Presenter & Discussion Moderator
Arnab Chakravarti, MD
Associate Professor of Radiation Oncology
Massachusetts General Hospital
Harvard Medical School
Susan C. Pannullo, MD
Director of Neuro-Oncology
Department of Neurological Surgery
Weil Cornell Medical College
New York, NY
Michael Vogelbaum, MD, PhD
Brain Tumor Institute
Physician CME: 1.0
CREDIT FOR THIS PROGRAM IS AVAILABLE FOR PHYSICIANS, ONLY
New treatments and creative combinations of existing treatments have translated into longer survival periods and improved quality of life for patients with primary malignant gliomas. A turning point in the treatment of this disease was achieved when a simultaneous chemotherapy and radiation combination approach was shown to be significantly efficacious in extending survival for glioblastoma patients. Combination chemoradiation is now considered the standard of care for newly diagnosed glioblastoma. How well this approach may work for other high-grade gliomas is being explored. Another significant development that is beginning to change the treatment paradigm is the greater understanding of the cellular biology and physiologic behaviors of different tumors. The discovery of different molecular markers is leading to more refined, targeted treatments , eventually allowing tailored treatments to patients with specific tumor types. Program Developer/Facilitator
. Target Audience
This educational activity is designed to meet the needs of neuro-oncologists, neurosurgeons, radiation oncologists, and medical oncologists interested in the treatment of primary gliomas.
Upon completion of this educational activity, the participant should be able to:
Review the importance of molecular markers in predicting tumor behavior and response.
Describe combination chemoradiation – the current standard of care for glioblastoma – and its potential applicability to other high-grade gliomas.
Identify emerging therapeutic modalities.
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity.
This educational activity may contain discussion of published and/or investigational uses of pharmacologic agents. Some uses may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices in their presentations.
Dr. Chakravarti indicates he has no actual or potential conflict of interest.
Dr. Pannullo discloses that she has received research funds from Cytec, Genentech, MGI Pharma, Novocare, and NTI Pharmaceuticals. She is also on speakers' bureaus for MGI Pharma and Schering-Plough.
Dr. Vogelbaum discloses that he has received consultant fees from Genentech, MGI Pharma, and Schering-Plough.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH, Inc. and Medical Communications Media, Incorporated. AKH, Inc. is accredited by the ACCME to provide continuing medical education for physicians.
AKH, Inc. designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credits TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Commercial Support Statements
Supported through an educational grant from Schering-Plough.
Please turn off all pop-up blockers and click on the "Start Program" icon at the bottom of the page. If you have not previously registered with this website, you will be taken to the login/registration page where you will be able to register as a new CMEcorner.com member. If you have previously registered, you will be asked to verify or correct existing registration information. When ready, click on the "Start Program" icon.
The next screen will be a brief pre-program survey. Please complete the survey and click on the "Done" button on the bottom of the page. Please wait while you are connected to the video server. This program, roundtable session, post-test, and evaluation will take approximately 60 minutes to complete.
Instructions for completing and submitting the post-test are provided on the post-test screen. A minimum score of 70% on the post-test is required for a CME certificate. One retake is permitted.
©2008 Medical Communications Media, Inc. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational program are those of the presenters and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., or Schering-Plough Corporation. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other healthcare professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.